ScholarLens Back to search
2007•PubMedRequires access

[Effect of bone marrow stromal cells transfected with interleukin 18 on growth of intracranial glioma in rats].

Chunhui Li, Baohua Jiao

Open publisher page 2 citations

Abstract

BACKGROUND & OBJECTIVE: Because of the invasion and immune escape characteristics, surgical resection, radiotherapy, and chemotherapy had no definite curative effects on intracranial glioma. Because bone marrow stromal cells (BMSCs) can track migrating cells, and interleukin 18 (IL-18) can enhance antitumor immune reaction, this study was to explore the effect of IL-18-transfected BMSCs on growth of glioma in rats. METHODS: Pure BMSCs were obtained by culturing rat bone marrow cells and identified by flow cytometry (FCM). BMSCs were transfected with retrovirus LXSN/IL-18 to prepare BMSCs/IL-18. IL-18 genetic transcription and expression were assessed by reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence. The characteristic variations of BMSCs were detected by MTT assay, FCM, and immunofluorescence. The effect of BMSCs/IL-18 on activation of T cells was evaluated by ELISA. Glioma-bearing rats were divided into BMSCs group, BMSCs/IL-18 group, PBS group, and control group and received relevant treatments. The effect of BMSCs/IL-18 on growth of glioma was observed. RESULTS: IL-18 gene was expressed stably in BMSCs/IL-18. The proliferation speed of BMSCs/IL-18 was slower than that of BMSCs. The secretion of interferon-gamma (IFN-gamma) from rat spleen lymphocytes in BMSCs/IL-18 group was 9 times more than that in BMSCs group. Tumor volume was (18.26+/-6.84) mm(3) in BMSCs group, (6.37+/-1.52) mm(3) in BMSCs/IL-18 group, (22.48+/-6.02) mm(3) in PBS group, and (21.06+/-5.83) mm(3) in control group; survival time of the rats was (25.3+/-6.4) days, (84.7+/-16.3) days, (21.6+/-4.7) days, and (22.5+/-6.2) days, respectively. After transplantation of BMSCs/IL-18, CD4(+) T cells in glioma were increased to 37.7+/-3.5 and CD8(+) T cells were increased to 32.3+/-4.5 in each field of view (x200). CONCLUSION: BMSCs/IL-18 could express IL-18 gene stably, and have definite therapeutic effect on glioma in rats.

About this research paper

What this paper is about

BACKGROUND & OBJECTIVE: Because of the invasion and immune escape characteristics, surgical resection, radiotherapy, and chemotherapy had no definite curative effects on intracranial glioma. Because bone marrow stromal cells (BMSCs) can track migrating cells, and interleukin 18 (IL-18) can enhance antitumor immune reaction, this study was to explore the effect of IL-18-transfected BMSCs on growth of glioma in rats. METHODS: Pure BMSCs were obtained by culturing rat bone marrow cells and identified by flow cytometry (FCM). BMSCs were transfected with retrovirus LXSN/IL-18 to prepare BMSCs/IL-18. IL-18 genetic transcription and expression were assessed by reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence. The characteristic variations of BMSCs were detected by MTT assay, FCM, and immunofluorescence. The effect of BMSCs/IL-18 on activation of T cells was evaluated by ELISA. Glioma-bearing rats were divided into BMSCs group, BMSCs/IL-18 group, PBS group, and control group and received relevant treatments. The effect of BMSCs/IL-18 on growth of glioma was observed. RESULTS: IL-18 gene was expressed stably in BMSCs/IL-18. The proliferation speed of BMSCs/IL-18 was slower than that of BMSCs. The secretion of interferon-gamma (IFN-gamma) from rat spleen lymphocytes in BMSCs/IL-18 group was 9 times more than that in BMSCs group. Tumor volume was (18.26+/-6.84) mm(3) in BMSCs group, (6.37+/-1.52) mm(3) in BMSCs/IL-18 group, (22.48+/-6.02) mm(3) in PBS group, and (21.06+/-5.83) mm(3) in control group; survival time of the rats was (25.3+/-6.4) days, (84.7+/-16.3) days, (21.6+/-4.7) days, and (22.5+/-6.2) days, respectively. After transplantation of BMSCs/IL-18, CD4(+) T cells in glioma were increased to 37.7+/-3.5 and CD8(+) T cells were increased to 32.3+/-4.5 in each field of view (x200). CONCLUSION: BMSCs/IL-18 could express IL-18 gene stably, and have definite therapeutic effect on glioma in rats.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND & OBJECTIVE: Because of the invasion and immune escape characteristics, surgical resection, radiotherapy, and chemotherapy had no definite curative effects on intracranial glioma. Because bone marrow stromal cells (BMSCs) can track migrating cells, and interleukin 18 (IL-18) can enhance antitumor immune reaction, this study was to explore the effect of IL-18-transfected BMSCs on growth of glioma in rats. METHODS: Pure BMSCs were obtained by culturing rat bone marrow cells and identified by flow cytometry (FCM). BMSCs were transfected with retrovirus LXSN/IL-18 to prepare BMSCs/IL-18. IL-18 genetic transcription and expression were assessed by reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence. The characteristic variations of BMSCs were detected by MTT assay, FCM, and immunofluorescence. The effect of BMSCs/IL-18 on activation of T cells was evaluated by ELISA. Glioma-bearing rats were divided into BMSCs group, BMSCs/IL-18 group, PBS group, and control group and received relevant treatments. The effect of BMSCs/IL-18 on growth of glioma was observed. RESULTS: IL-18 gene was expressed stably in BMSCs/IL-18. The proliferation speed of BMSCs/IL-18 was slower than that of BMSCs. The secretion of interferon-gamma (IFN-gamma) from rat spleen lymphocytes in BMSCs/IL-18 group was 9 times more than that in BMSCs group. Tumor volume was (18.26+/-6.84) mm(3) in BMSCs group, (6.37+/-1.52) mm(3) in BMSCs/IL-18 group, (22.48+/-6.02) mm(3) in PBS group, and (21.06+/-5.83) mm(3) in control group; survival time of the rats was (25.3+/-6.4) days, (84.7+/-16.3) days, (21.6+/-4.7) days, and (22.5+/-6.2) days, respectively. After transplantation of BMSCs/IL-18, CD4(+) T cells in glioma were increased to 37.7+/-3.5 and CD8(+) T cells were increased to 32.3+/-4.5 in each field of view (x200). CONCLUSION: BMSCs/IL-18 could express IL-18 gene stably, and have definite therapeutic effect on glioma in rats.

Key concepts: Stromal cell, Glioma, Bone marrow, Transfection, Immune system, Flow cytometry, Chemistry, Reverse transcription polymerase chain reaction

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
[Effect of bone marrow stromal cells transfected with interleukin 18 on growth of intracranial glioma in rats]. — Research Paper | ScholarLens